As focus of this study was to assess the efficacy and identify a target of pharmaceutical inhibitors of CDK9 in esophageal adenocarcinoma and MYC did not show consistent alterations after CDK9 inhibitor treatment, we chose to study MCL-1 instead of MYC as the CDK9 target in this study. Here, CDK9 is linked to esophageal adenocarcinoma.